Select language:  
1800 620 420
Close menu

Developing mutation-specific targeted therapies for AML – “a new era of medicine has begun”

Dr Daniel Thomas brought us up-to-speed on his multi-faceted work in the field of myeloid leukaemia.

  • Acute myeloid leukaemia
  • Research
Read more
A/Prof Dan Thomas

Deborah’s one of the first Aussies to have CAR T-cell therapy for CLL

Thirty-one days after Deborah Sims had an infusion of her own re-engineered T-cells in September, she was told her aggressive CLL was in remission and she may well be cured.

  • Chronic lymphocytic leukaemia
Read more

Expert Series interview with Professor Constantine Tam on CLL–now and into the future

We spoke to Professor Con Tam on the latest in CLL research.

  • Chronic lymphocytic leukaemia
  • Research
Read more
Professor Constantine Tam

Familial research key to blood cancer prevention strategy

The Australian Familial Haematological Cancer Study (AFHCS) leads the world in the field and has a research cohort of more than 200 families with a history of blood cancer.

  • Acute myeloid leukaemia
  • Myelodysplastic syndromes
  • Research
Read more
AFHCS research team

PhD scholarships focused on improving outcomes for people with AML and MPN

Basit Salik, Dr Jamie Kuzich and Dr Julian Grabek are the successful recipients of the 2021 PhD Scholarships.

  • Acute myeloid leukaemia
  • Myeloproliferative neoplasms
  • Research
Read more
Illustration of a microscope, test tubes, and clipboard

Drug discovery has remarkable potential for high-risk childhood leukaemia

Dr Michelle Henderson's research is laying the groundwork to develop a promising new therapy for infant ALL.

  • Acute lymphoblastic leukaemia
  • Research
Read more
Dr Michelle Henderson in the lab

From PhD in Melbourne to postdoc in New York

New York-based, Aussie researcher Matt Witkowski has his sights set on improving the effectiveness of CAR T-cell therapy.

  • Acute lymphoblastic leukaemia
  • Research
Read more
Matthew Witkowski

Research aims to improve QOL by decreasing treatment toxicity

Kate Vandyke is leading exciting research examining whether a new inhibitor can be used to prepare myeloma patients for therapies and increase their efficacy.

  • Myeloma
  • Research
Read more
Kate van Dyke

Clinical trials critical to finding curative therapies for MPN

Professor David Ross discusses the "massive explosion" of recent clinical trial activity in MPN.

  • Myeloproliferative neoplasms
  • Research
Read more
Dr David Ross and others in Tokyo

Improving outcomes for Australians with an MPN 

Dr Liesl Butler is investigating the gene mutations and biological pathways that lead to the development of MPN.

  • Myeloproliferative neoplasms
  • Research
Read more
Gene